CNTX Context Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1842952 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-66.0%
TTM EPS YoY-91.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-84.3%
ROA-75.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets15.1%
Debt / equity0.00x
Current ratio6.59x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $31.86M | $22.70M | $17.78M | $7.09M | $3.81M |
| SG&A expense | $7.85M | $7.22M | $7.29M | $7.79M | $3.63M |
| Operating income | -$39.70M | -$29.92M | -$25.07M | -$15.38M | -$10.53M |
| Interest expense | — | — | — | — | $64,240 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$36.12M | -$26.73M | -$23.96M | -$14.84M | -$10.46M |
| EBITDA | -$39.69M | -$29.91M | -$25.06M | -$15.37M | -$10.53M |
| EPS (basic) | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 |
| EPS (diluted) | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 |
| Weighted avg. shares (diluted) | 95.19M | 58.42M | 15.97M | 15.97M | 2.83M |
| Banking | |||||
| Net interest income | — | — | $1.16M | $547,268 | -$64,240 |
| Balance sheet | |||||
| Cash & equivalents | $66.00M | $94.43M | $14.45M | $35.50M | $49.69M |
| Current assets | $68.35M | $97.90M | $16.05M | $37.85M | $51.26M |
| PP&E, net | $29,656 | $11,959 | $15,524 | $27,568 | $0 |
| Total assets | $68.49M | $98.13M | $16.06M | $37.97M | $51.31M |
| Current liabilities | $8.02M | $2.75M | $4.19M | $3.21M | $3.03M |
| Total liabilities | $8.02M | $2.86M | $4.19M | $3.21M | $3.03M |
| Shareholders' equity | $60.47M | $95.27M | $11.87M | $34.76M | $48.27M |
| Shares outstanding | 91.88M | 89.70M | 15.97M | 15.97M | 15.97M |
| Cash flow statement | |||||
| Operating cash flow | -$26.39M | -$14.56M | -$21.05M | -$13.55M | -$8.80M |
| Capital expenditure | $33,948 | $7,316 | $0 | $36,836 | $0 |
| Free cash flow | -$26.42M | -$14.56M | -$21.05M | -$13.59M | -$8.80M |
| Investing cash flow | -$2.03M | -$14.76M | $0 | -$536,836 | -$250,000 |
| Financing cash flow | -$15,268 | $109.29M | $0 | -$102,071 | $58.39M |
| Depreciation & amortization | $16,251 | $10,881 | $12,044 | $9,268 | $0 |
| Stock-based compensation | $1.33M | $841,867 | $1.08M | $976,440 | $511,079 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.